新型口服木瓜基预防性与治疗性疫苗控制不同人兽共患带绦虫寄生虫:当前进展
本文综述以番木瓜(Carica papaya)组织培养为生物工厂系统开发低成本口服疫苗的进展,该疫苗基于带绦虫种间高度保守的保护性抗原KETc7,由转KETc7基因木瓜细胞水提物与野生型番木瓜细胞驱虫水提物组成,兼有预防与治疗双重作用,旨在单一疫苗控制地方性流行区不同带绦虫感染,尤其适用于传统注射接种受物流与经济限制的地区。
要点
- KETc7为带绦虫种间高度保守的保护性抗原,已在番木瓜组织培养平台表达。
- 疫苗由转KETc7基因木瓜细胞水提物与野生型番木瓜细胞驱虫水提物组成。
- 转基因组与非转基因组番木瓜细胞悬浮培养已优化,可实现可扩展生产。
核心结论
- 综述认为,整合带绦虫寄生虫生物学知识与植物生物技术进展,双作用口服疫苗可作为地方性流行区用一种疫苗控制不同带绦虫感染的策略,尤其适用于传统注射接种受物流与经济限制的地区。
研究设计与样本
- 本文为综述,总结以番木瓜组织培养为生物工厂系统开发针对人兽共患带绦虫寄生虫的新型低成本口服疫苗的进展。
主要发现
- 带绦虫种间高度保守的保护性抗原KETc7已在番木瓜组织培养平台表达。
- 番木瓜不仅作为口服免疫的高效载体,还具有内在驱虫特性。
- 带绦虫口服木瓜疫苗制剂由转KETc7基因木瓜细胞水提物与野生型番木瓜细胞驱虫水提物组成。
- 转基因组与非转基因组番木瓜细胞悬浮培养已在可重复条件下优化,可实现疫苗可扩展生产。
- 针对棘球蚴病的定向免疫规划已使传播显著减少,但全球根除尚未实现;囊尾蚴病持续接种研究已证明阻断传播循环可行。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zoonotic infections caused by Taenia and Echinococcus species are the most significant Taeniid parasitic diseases affecting human and animal health, particularly in regions with poor sanitation. Vaccination of intermediate hosts has proven effective in controlling these parasitic infections. In the case of Echinococcosis, targeted immunization programs have led to marked reductions in transmission, although global eradication remains unachieved. Similarly, sustained vaccination studies for cysticercosis have demonstrated the feasibility of interrupting transmission cycles. This review summarizes the current state of progress in the development of a novel, low-cost oral vaccine against zoonotic Taeniid parasites employing Carica papaya tissue cultures as a biofactory system. KETc7, a highly conserved protective antigen among Taeniid species, has been expressed in this plant tissue culture-based platform. C. papaya serves not only as an efficient vehicle for oral immunization but also exhibits intrinsic anthelmintic properties. The Taeniid oral papaya vaccine formulation consists of aqueous extracts from KETc7-transgenic papaya cells, combined with anthelmintic aqueous extracts derived from wild-type C. papaya cells. Importantly, transgenic and non-transgenic C. papaya cells suspension cultures were optimized under reproducible conditions to enable scalable production for the vaccine. By integrating biological knowledge of Taeniid parasites with advances in plant biotechnology, this review highlights the advances of a dual-action oral vaccine, both preventive and therapeutic, as a strategy to control with one vaccine different Taeniid infections in endemic regions, particularly where conventional injectable vaccination is limited by logistical and economic restrictions.
引用
- Hernández M, Caltempa AO, Villalobos N, et al. Novel Oral papaya-based preventive and therapeutic vaccine for controlling different zoonotic Taeniid parasites: Current advances. Vaccine. 2025. PMID: 41066986. doi:10.1016/j.vaccine.2025.127818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。